Budget Impact Analysis Of Adopting Evolocumab In The Brazilian Private Healthcare System For Patients With Uncontrolled LDL-C And High Cardiovascular Risk

Santos, RF dos; Alves, FP; Urbich, Michael; Villa, Guillermo; Farsky, PS

doi:10.1016/j.jval.2017.08.2838

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estimates for health system costs for each health state and for events were extracted from the literature for São Paulo. An annual baseline health cost of USD 191 was assumed for both uncontrolled and controlled hypertension patients [ 33 ] and event costs were estimated at USD 1,522 for CHD [ 34 ] and USD 5,864 for stroke [ 35 , 36 ]. Additional costs resulting from productivity loss through partial or total absence from work were estimated from the proportional per-capita income earned in one working day [ 33 ].…”

Section: Methodsmentioning

confidence: 99%

Population health impact and economic evaluation of the CARDIO4Cities approach to improve urban hypertension management

Reiker

Rosiers

Boch

et al. 2023

PLOS Glob Public Health

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of mortality worldwide, with 80% of that mortality occurring in low- and middle-income countries. Hypertension, its primary risk factor, can be effectively addressed through multisectoral, multi-intervention initiatives. However, evidence for the population-level impact on cardiovascular (CV) event rates and mortality, and the cost-effectiveness of such initiatives is scarce as long-term longitudinal data is often lacking. Here, we model the long-term population health impact and cost-effectiveness of a multisectoral urban population health initiative designed to reduce hypertension, conducted in Ulaanbaatar (Mongolia), Dakar (Senegal), and in the district of Itaquera in São Paulo (Brazil) in collaboration with the local governments. We based our analysis on cohort-level data among hypertensive patients on treatment and control rates from a real-world effectiveness study of the CARDIO4Cities approach (built on quality of care, early access, policy reform, data and digital, Intersectoral collaboration, and local ownership). We built a decision tree model to estimate the CV event rates during implementation (1–2 years) and a Markov model to project health outcomes over 10 years. We estimated the number of CV events averted and quality-adjusted life-years gained (QALYs through the initiative and assessed its cost-effectiveness based on the costs reported by the funder using the incremental cost effectiveness ratio (ICER) and published thresholds. A one-way sensitivity analysis was performed to assess the robustness of the results. The modelled patient cohorts included 10,075 patients treated for hypertension in Ulaanbaatar, 5,236 in Dakar, and 5,844 in São Paulo. We estimated that 3.3–12.8% of strokes and 3.0–12.0% of coronary heart disease (CHD) events were averted during 1–2 years of implementation in the three cities. We estimated that over the subsequent 10 years, 3.6–9.9% of strokes, 2.8–7.8% of CHD events, and 2.7–7.9% of premature deaths would be averted. The estimated ICER was USD 748 QALY gained in Ulaanbaatar, USD 3091 in Dakar, and USD 784 in São Paulo. With that, the intervention was estimated to be cost-effective in Ulaanbaatar and São Paulo. For Dakar, cost-effectiveness was met under WHO-CHOICE standards, but not under more conservative standards adjusted for purchasing power parity (PPP) and opportunity costs. The findings were robust to the sensitivity analysis. Our results provide evidence that the favorable impact of multisector systemic interventions designed to reduce the hypertension burden extend to long-term population-level CV health outcomes and are likely cost-effective. The CARDIO4Cities approach is predicted to be a cost-effective solution to alleviate the growing CVD burden in cities across the world.

show abstract